Arcutis raised its full-year 2026 net revenue guidance to $525 million to $540 million, from its prior range of $480 million to $495 million. Watanabe said there are roughly 1 million atopic dermatitis patients in that age range and limited approved treatment options, particularly nonsteroidal ones. It has begun enrolling atopic dermatitis patients in the remaining single-ascending-dose cohorts and plans to begin the multiple-ascending-dose portion. About Arcutis Biotherapeutics (NASDAQ:ARQT)Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo.